Hidradenitis Suppurativa Treatment Market Size, Share, Growth, Trends, and Global Industry Analysis: By Clinical Stage (Hurley Stage 1, Hurley Stage 2, Hurley Stage 3) Drug Type (Biologics, Antibiotics, Hormonal therapy, Immune suppurativa drugs, Pain medications Others) By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) and Region  

Hidradenitis Suppurativa Treatment Market size was valued at US$ 721.9 million in 2022 and is expected to grow at a prominent growth rate of 4.50% from 2023 to 2029. The global market provides a detailed overview of the global Hidradenitis Suppurativa Treatment market, and that can be segmented by Clinical Stage, by Drug Type, and by Distribution Channel. By Clinical Stage, the global Hidradenitis Suppurativa Treatment market has been segmented into Hurley Stage 1, Hurley Stage 2, and Hurley Stage 3. The Hurley stage 1 Suppurativa Treatment segment is likely to be the largest and fastest-growing segment in terms of type. Based on Drug type, the global Hidradenitis Suppurativa Treatment market is segmented into Biologics, Antibiotics, Hormonal therapy, Immune suppurativa drugs, Pain medications, and Others. Among these, the biologics segment is expected to have the fastest-growing market during the forecast period.

Hidradenitis Suppurativa Treatment Market Key Developments:

• In Feb 2019, InflaRx N.V., which is recognized for creating novel therapies to treat inflammatory diseases, recently released new clinical results including the use of IFX-1 in patients with moderate to severe Hidradenitis Suppurativa.
• In March 2022, MoonLake began testing nanobody, sonelokimab in a Phase II clinical trial to treat moderate-to-severe hidradenitis suppurativa (HS). By blocking the IL-17A/A, IL-17A/F, and IL-17F/F dimers that induce inflammation in the body, sonelokimab may be able to cure inflammatory conditions.